We also evaluated the relationship between the AUC of drug sensitivity and common somatic mutations in AML (Fig. 1C) and observed a lower AUC of samples with NPM1 mutation to the various FLT3 inhibitors, such as crenolanib (P < 0.01), quizartinib (P < 0.01), and gilteritinib (P = 0.07) (Fig. 1C). Here, FLT3 is linked to acute myeloid leukemia.